Published in CEN Case Rep on December 02, 2014
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol (2005) 5.64
Total and cardiovascular mortality in relation to cigarette smoking, serum cholesterol concentration, and diastolic blood pressure among black and white males followed up for five years. Am Heart J (1984) 3.25
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood (2011) 2.82
Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood (1992) 2.81
Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol (2003) 2.74
Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem (2005) 2.64
Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid (2012) 2.21
Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol (2010) 2.20
Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum (2006) 2.20
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood (2009) 2.19
Amyloidosis-associated kidney disease. J Am Soc Nephrol (2006) 2.12
Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol (2008) 2.08
The link between hypertension and nephrosclerosis. Am J Kidney Dis (1995) 1.77
Sensitivity, specificity, and predictive value of abdominal fat aspiration for the diagnosis of amyloidosis. Arthritis Rheum (1989) 1.76
Two distinct clinical courses of renal involvement in rheumatoid patients with AA amyloidosis. J Rheumatol (2006) 1.75
Subcutaneous fat tissue for diagnosis and studies of systemic amyloidosis. Acta Histochem (2006) 1.32
Sonographic evaluation of renal failure. Am J Kidney Dis (2000) 1.11
Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis. Haematologica (2008) 1.09
Diagnosis of amyloidosis by abdominal fat aspiration. Analysis of four years' experience. Am J Med (1987) 1.04
Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney. Nephrol Dial Transplant (2011) 0.94
Predominantly vascular amyloid deposition in the kidney in patients with minimal or no proteinuria. Clin Nephrol (1983) 0.91
Evaluation of abdominal fat pad aspiration cytology and grading for detection in systemic amyloidosis. Acta Cytol (2007) 0.86
A clinicopathological analysis in a large cohort of Chinese patients with renal amyloid light-chain amyloidosis. Nephrol Dial Transplant (2012) 0.86
Diagnostic value of bone marrow biopsy in patients with renal disease secondary to familial Mediterranean fever. Kidney Int (1993) 0.85